Previous 10 | Next 10 |
2023-03-31 21:25:09 ET Avadel Pharmaceuticals plc (AVDL) Q4 2022 Earnings Conference Call March 30, 2023 8:30 AM ET Company Participants Austin Murtagh – Stern Investor Relations Greg Divis – Chief Executive Officer Jennifer Gudeman – Senior ...
2023-03-30 07:44:45 ET Avadel Pharmaceuticals press release ( NASDAQ: AVDL ): Q4 GAAP EPS of -$0.44 misses by $0.17 . Cash, cash equivalents and marketable securities were $96.5 million as of December 31, 2022.The Company extended the maturity of $96.2 million of its c...
• LUMRYZ™ NDA amendment filed March 1 requesting FDA final approval • Received FDA authorization to import LUMRYZ in advance of final approval decision; shortens timeline between potential approval and product availability • Secured $200 milli...
2023-03-30 05:16:26 ET Avadel Pharmaceuticals ( NASDAQ: AVDL ) priced its underwritten public offering of 10M shares, nominal value $0.01/share in the form of ADS and 4.7M Series B Non-Voting Convertible Preferred Shares, convertible into ordinary shares on a one-for-one ...
DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 30, 2023, to pro...
DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the pricing of an underwritten public offering of 10,000,001 of its ordinary sh...
2023-03-29 17:08:55 ET Avadel Pharmaceuticals ( NASDAQ: AVDL ) on Wednesday said it had entered into a royalty agreement to support the potential commercialization of its sleep disorder drug Lumryz. The company said it had entered into a deal with RTW Investments and certain o...
DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is commencing an underwritten public offering of its ordinary shares, n...
– In parallel, extended maturity on $96.2 million of convertible notes to April 1, 2027 – Strategic financings strengthen the company’s balance sheet in advance of potential commercialization of LUMRYZ DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharm...
2023-03-22 08:21:40 ET 89bio ( ETNB ) +50% on topline data for NASH candidate. GameStop ( GME ) +48% on Q4 earnings. Telesis Bio ( TBIO ) +17% on Q4 earnings. Pyxis Oncology ( PYXS ) +11% on Q4 earnings. Ollie's Bargain O...
News, Short Squeeze, Breakout and More Instantly...
Avadel Pharmaceuticals plc Company Name:
AVDL Stock Symbol:
NASDAQ Market:
Avadel Pharmaceuticals plc Website:
DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Ind...
2024-05-29 06:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – – Presentations highlight Avadel’s continued commitment to address gaps in narcolepsy care – DUBLIN, May 22, 2024 (GLOBE NEWSWIRE) -...